bispecific

Biparatopic antibodies (bpAbs) are bispecific antibodies which bind distinct, non-overlapping epitopes on an antigen. This unique binding mode allows for superior affinity and specificity, promotes antagonism, locks target conformation, and results in higher-order target clustering. The antibody-target complexes can elicit strong agonism, increase immune effector function, or result in rapid target downregulation and lysosomal trafficking.

This month, two high-profile deals for bispecific antibodies targeting the PD-1/PD-L1 and VEGF pathways were announced. The DealsOn November 14, Merck announced its licensing agreement with LaNova Medicines for LM-299, an investigational PD-1/VEGF bispecific antibody. Merck is committing up to

Bispecific antibodies fight cancer via unique mechanisms. Biointron highlights how bsAbs target multiple pathways to expand therapeutic impact.

Bispecific antibodies are rapidly transforming the therapeutic landscape, especially in oncology and autoimmune diseases. Such recombinant molecules can bind to two different antigens at the same time, offering greater specificity in targeting disease pathways. Since their introduction, the area of bispecifics has held tremendous promise in oncological cancers like multiple myeloma and lymphomas.

High-throughput antibody expression drives speed and scale. Biointron applies automated platforms to deliver reproducible antibodies for research and therapy.

Innovative antibody formats like VHHs, scFvs, and ADCs expand therapeutic options. Biointron explores how these formats drive flexibility and efficacy.

Explore the role of bispecific antibodies (bsAbs) in cancer therapy and beyond, and learn how dual-targeting enhances immune responses and overcomes monoclonal limits.

The 15th World Bispecifics Summit in Boston showcased breakthroughs. Biointron shares highlights shaping the future of bispecific antibody therapeutics.

Explore how bispecific antibodies (BsAbs) transform in vivo research by enhancing oncology, immunotherapy, and drug development through dual-targeting precision.

The approval of Eli Lilly’s Kisunla (donanemab-azbt), a humanized IgG1 monoclonal antibody, is just one of the major advancements in the treatment of Alzheimer's disease (AD)! This drug is now available in the US for adults with early symptomatic AD, including those with mild cognitive impairment (MCI) and mild dementia stage of AD with amyloid pathology.

Explore key highlights from PEGS 2024, featuring breakthroughs in antibody engineering, immunotherapy, ADC development, AI-driven discovery, and protein science.

scFvs combine compact design with strong binding. Biointron explores their history, therapeutic applications, and role in diagnostics and research innovation.

Bispecific ADCs advance oncology. Biointron shows how dual-targeted antibody-drug conjugates improve precision, efficacy, and patient outcomes in cancer treatment.

Bispecific antibody-drug conjugates (BsADCs) are a new class of therapeutic drugs being developed to fight cancer. They combine the dual targeting ability of bispecific antibodies with the cell-killing power of cytotoxic drugs. BsADCs are designed to deliver cytotoxic drugs directly to cancer cells, while minimizing damage to healthy cells. While they are still in development, several exciting advances have occurred recently.

From hybridomas to recombinant platforms, antibody production has evolved. Biointron reveals ten insights into methods that ensure reliable supply and scientific progress.